Details for New Drug Application (NDA): 022110
✉ Email this page to a colleague
NDA 022110 describes VIBATIV, which is a drug marketed by Cumberland and is included in one NDA. It is available from one supplier. There is one patent protecting this drug. Additional details are available on the VIBATIV profile page.
The generic ingredient in VIBATIV is telavancin hydrochloride. One supplier is listed for this compound. Additional details are available on the telavancin hydrochloride profile page.
The generic ingredient in VIBATIV is telavancin hydrochloride. One supplier is listed for this compound. Additional details are available on the telavancin hydrochloride profile page.
Summary for 022110
| Tradename: | VIBATIV |
| Applicant: | Cumberland |
| Ingredient: | telavancin hydrochloride |
| Patents: | 1 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 022110
Generic Entry Date for 022110*:
Constraining patent/regulatory exclusivity:
Dosage:
POWDER;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 022110
Suppliers and Packaging for NDA: 022110
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110 | NDA | Cumberland Pharmaceuticals Inc. | 66220-315 | 66220-315-11 | 1 VIAL, SINGLE-DOSE in 1 CARTON (66220-315-11) / 50 mL in 1 VIAL, SINGLE-DOSE |
| VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110 | NDA | Cumberland Pharmaceuticals Inc. | 66220-315 | 66220-315-22 | 12 VIAL, SINGLE-DOSE in 1 CARTON (66220-315-22) / 50 mL in 1 VIAL, SINGLE-DOSE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | POWDER;INTRAVENOUS | Strength | EQ 250MG BASE/VIAL | ||||
| Approval Date: | Sep 11, 2009 | TE: | RLD: | Yes | |||||
| Patent: | 7,531,623 | Patent Expiration: | Jan 1, 2027 | Product Flag? | Substance Flag? | Y | Delist Request? | ||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | POWDER;INTRAVENOUS | Strength | EQ 750MG BASE/VIAL | ||||
| Approval Date: | Sep 11, 2009 | TE: | RLD: | Yes | |||||
| Patent: | 7,531,623 | Patent Expiration: | Jan 1, 2027 | Product Flag? | Substance Flag? | Y | Delist Request? | ||
Expired US Patents for NDA 022110
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Cumberland | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-002 | Sep 11, 2009 | 7,351,691 | ⤷ Start Trial |
| Cumberland | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-002 | Sep 11, 2009 | 6,858,584 | ⤷ Start Trial |
| Cumberland | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-001 | Sep 11, 2009 | 6,635,618 | ⤷ Start Trial |
| Cumberland | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-001 | Sep 11, 2009 | 8,158,580 | ⤷ Start Trial |
| Cumberland | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-002 | Sep 11, 2009 | 6,872,701 | ⤷ Start Trial |
| Cumberland | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-002 | Sep 11, 2009 | 7,544,364 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
